RxDoctor Payments Data

Asu Rustemli, MD

Cardiovascular Disease · Toms River, NJNPI 1942452172

Payments from drug & device makers

$2,286in general payments, 2019–2025

Across 121 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$392
  • Novartis$378
  • AstraZeneca$204
  • Amgen$167
  • Johnson & Johnson$152
  • Novo Nordisk$137
  • plus $856 from 19 others

What the payments were for

  • Food & beverage$2,286100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,286 in reported general payments places this provider in the 45th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$315,008
Medicare patients
515
Services billed
3,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban231$298,997
EntrestoSacubitril/Valsartan100$113,991
FarxigaDapagliflozin Propanediol67$85,739
XareltoRivaroxaban61$70,725
Repatha SureclickEvolocumab37$42,603
Praluent PenAlirocumab17$21,838
Repatha SyringeEvolocumab20$20,572
BrilintaTicagrelor22$15,802
JardianceEmpagliflozin19$15,746
Atorvastatin Calcium520$5,503
Metoprolol Succinate305$4,780
Rosuvastatin Calcium262$4,415
Ezetimibe103$2,669
Losartan Potassium201$2,089
Carvedilol136$1,866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$116$298,997231 claims
NovartisEntresto$378$113,991100 claims
AstraZenecaFarxiga, Brilinta$204$101,54189 claims
Johnson & JohnsonXarelto$152$70,72561 claims
Boehringer IngelheimJardiance$121$15,74619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →